Clearside Biomedical gets $20M for drug-device combo for blindness disorders
Clearside Biomedical will use the Series C round to further clinical trials for its drug-device combination for diseases of the eye that cause blindness.
Clearside Biomedical will use the Series C round to further clinical trials for its drug-device combination for diseases of the eye that cause blindness.